In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N = 72), tabalumab 100 mg (N = 74), or tabalumab 300 mg (N = 74), each in combination with dexamethasone 20 mg and subcutaneous bortezomib 1Á3 mg/m 2 on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6Á6, 7Á5 and 7Á6 months for the tabalumab 100, 300 mg and placebo groups, respectively (tabalumab 100 mg vs. placebo Hazard ratio (HR) [95% confidence interval (CI)] = 1Á13 [0Á80-1Á59], P = 0Á480; tabalumab 300 mg vs. placebo HR [95% CI] = 1Á03 [0Á72-1Á45], P = 0Á884). The most commonly-reported treatment-emergent adverse events were thrombocytopenia (37%), fatigue (37%), diarrhoea (35%) and constipation (32%). Across treatments, patients with low baseline BAFF (also termed TNFSF13B) expression (n = 162) had significantly longer mPFS than those with high BAFF expression (n = 55), using the 75th percentile cut-off point ( 
Multiple myeloma is a cancer of plasma cells that is typically characterized by a monoclonal protein in the blood, urine or both. In 2016, there are expected to be 30 330 new cases of multiple myeloma and 12 650 related deaths in the United States (Siegel et al, 2016) . Multiple myeloma is treatable, but remains incurable, despite new treatment options and advances in understanding the molecular pathogenesis of the disease. Multiple classes of drugs have been approved by the US Food and Drug Administration in the past decade for treatment of relapsed or refractory multiple myeloma, including first-and second-generation proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), histone deacetylase inhibitors (e.g., panobinostat), and immunomodulatory agents (e.g., lenalidomide, pomalidomide). These agents significantly improved survival and a strong rationale exists for combining them with novel agents that target other aberrant molecular pathways in multiple myeloma, including pathways that promote treatment resistance (Laubach et al, 2014) . Combination therapies involving lenalidomide (Zagouri et al, 2015) , pomalidomide (Hanaizi et al, 2015) , bortezomib (Harrison et al, 2015) , carfilzomib (McBride et al, 2015) , or ixazomib (Gentile et al, 2015; Kumar et al, 2015) with dexamethasone, as well as panobinostat with bortezomib and dexamethasone San-Miguel et al, 2014) or carfilzomib (Berdeja et al, 2015) , have shown higher response rates than monotherapy or single-agent therapy with dexamethasone. More recently, 3-drug combinations including bortezomib, carfilzomib or ixazomib with lenalidomide and dexamethasone are emerging with superior efficacy, even in the relapsed setting (Gentile et al, 2015; Kim & Schmidt-Wolf, 2015; Stewart et al, 2015) . Several other classes of drugs are undergoing clinical development in relapsed multiple myeloma including a new proteasome inhibitor (marizomib), an oral proteasome inhibitor related to carfilzomib (oprozomib), a kinesin spindle protein inhibitor (filanesib), a cyclin-dependent kinase inhibitor (dinaciclib), a selective BCL2 inhibitor (ABT-199) and a pan PIM kinase inhibitor (LGH-447) (Rajkumar, 2016) .
Monoclonal antibodies (mAbs) have emerged as a promising treatment and can promote cytotoxicity through a number of mechanisms (Rajkumar, 2016) . Daratumumab, a monoclonal CD38 antibody, was the first mAb approved as a single agent in quadruple-refractory multiple myeloma (Poh, 2016) and is also being studied in combination with lenalidomide and dexamethasone (Lokhorst et al, 2013; Phipps et al, 2015) . Clinical trials of elotuzumab, a monoclonal immunoglobulin G1 (IgG1) antibody against Signalling Lymphocyte Activation Molecule Family member 7 (SLAMF7), in combination with lenalidomide or bortezomib and dexamethasone reported favourable outcomes (Jakubowiak et al, 2012; Lonial et al, 2015; Palumbo & Sonneveld, 2015) and led to its recent approval in combination with lenalidomide and dexamethasone in patents who have received 1-3 lines of therapy (Poh, 2016) .
B-cell activating factor (BAFF), also known as tumour necrosis factor superfamily 13b or B-lymphocyte stimulator (TNFSF13B), has generated considerable interest as an essential survival factor for normal and malignant B cells (Tai et al, 2006; Neri et al, 2007; Hengeveld & Kersten, 2015) . BAFF inhibits apoptosis of lymphoma, chronic lymphocytic leukaemia and multiple myeloma cells in vitro, and serum BAFF levels are elevated in patients with multiple myeloma (He et al, 2004; Moreaux et al, 2004; Haiat et al, 2006; Neri et al, 2007) . Tabalumab is a potent and selective fully human IgG4 monoclonal antibody with neutralizing activity against both membrane-bound and soluble BAFF (Manetta et al, 2014) . In nonhuman primates, tabalumab mediated a reduction in peripheral blood B cells without a concomitant reduction of BAFF-expressing monocytes, and no adverse treatment-related effects were noted clinically or pathologically at any dose tested [ (Breslin et al, 2015) ; unpublished data]. Using an in vivo adoptive transfer model with an interleukin-6 (IL6)-dependent multiple myeloma cell line engrafted in a human foetal bone chip in severe combined immunodeficiency mice, treatment with tabalumab caused a significant reduction in tumour burden, reduction in markers of bone destruction, and a 16-day survival advantage compared to mice receiving an isotype control antibody (Neri et al, 2007) .
On the basis of preclinical data showing that BAFF neutralization decreased osteoclast numbers (Neri et al, 2007) and that bortezomib demonstrated potent activity against multiple myeloma and also increased osteoblast number and function (Mukherjee et al, 2008) , a Phase 1 trial combining tabalumab and bortezomib was conducted and found the combination to be well-tolerated and active in the relapsed/ refractory multiple myeloma setting (Raje et al, 2016) . Interestingly, at 100 mg tabalumab, the lowest dose thought to provide full saturation of the target, non-response was observed among all multiple myeloma patients with very high baseline BAFF levels (>1500 pg/ml). Pharmacokinetics (PK) data from that study indicated a linearization of tabalumab clearance at doses of approximately 100 mg and above. On the basis of these results, we hypothesized that a dose of 300 mg might be necessary to provide an adequate level of target neutralization in patients with higher BAFF levels, thereby maximizing the probability of achieving the best possible treatment effect in this patient population. Thus, the Phase 2 study described in this report evaluated the efficacy and safety of tabalumab 100 and 300 mg combined with bortezomib and dexamethasone compared to placebo combined with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Methods

Patients
Eligible patients were at least 18 years of age, had active multiple myeloma, and had received 1-3 prior treatments. Patients had a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group scale, an estimated life expectancy of ≥12 weeks, adequate organ function, and had measureable disease as defined by ≥1 of the following: serum monoclonal protein ≥10 g/l, urine monoclonal light chain ≥200 mg/24 h, or involved serum free light chain (SFLC) level >10 mg/l provided the SFLC ratio is abnormal. Prior therapy with bortezomib was allowed if it resulted in at least a minimal response, without relapse or progression of multiple myeloma within 60 days of the last dose. Patients of reproductive potential were required to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug. Women of childbearing potential were required to have a negative serum pregnancy test prior to the first dose of study treatment. Patients were excluded for progressive disease within 60 days of, or less than a minimal response to, their most recent therapy with a proteasome inhibitor. Additional exclusion criteria included active or systemic infection; positive human immunodeficiency virus test; evidence of active hepatitis B or C; prior therapy with experimental agents targeting BAFF, including tabalumab; and peripheral neuropathy of Grade 2 or higher as defined by National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v. 4.0).
Patients provided written informed consent prior to study entry and each participating study centre complied with their Institutional Review Boards or Ethical Review Boards and the Declaration of Helsinki.
Study design and treatment
This multicentre, randomized, double-blind, placebo-controlled, 3-arm, Phase 2 study was conducted at 60 study centres in 15 countries between 2012 and 2014). It is registered at clinicaltrials.gov as NCT01602224. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS); best overall response, categorized as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease (PD); quality of response (QoR), which reflects the distribution of best overall responses across all categories (see Efficacy and Safety Assessments below for definition); duration of response; time to progression; time to next treatment; time to first skeletal-related event (SRE); and the incidence of clinically significant pain response. PK and immunogenicity evaluations were also performed.
Patients were randomly assigned 1:1:1 to receive placebo, tabalumab 100 mg or tabalumab 300 mg (administered intravenously [IV] over 30 min on Day 1), each in combination with dexamethasone (20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12) and bortezomib (1Á3 mg/m 2 subcutaneously
[SQ] on Days 1, 4, 8 and 11; Millennium Pharmaceuticals, Cambridge, Massachusetts) (Fig 1) . Study treatment was given in the following order: dexamethasone, blinded study drug or placebo, then bortezomib. Bortezomib was given SQ following the accepted standard of care and due to its improved safety profile compared to IV delivery (Moreau et al, 2011) . Bortezomib could be administered IV if the patient was unable to tolerate the SQ injection. Patients were treated until disease progression or unacceptable toxicity occurred, whichever came first, for a maximum of 8-10 cycles of treatment, each lasting 21 days. Treatment with tabalumab beyond the completion of bortezomib was not allowed in order to avoid confounding of combination and monotherapy treatment effects. If a patient had an evolving response after 8 cycles of treatment, the patient could receive an additional 2 cycles of the assigned therapy at the discretion of the investigator. An evolving response was defined as a consistent reduction (improvement) in the measureable serum M-protein, urine M-protein, and/or difference between the involved and uninvolved SFLC, OR an improvement in response category (for example, CR to sCR) from Cycle 6 Day 1 to Cycle 7 Day 1 AND from Cycle 7 Day 1 to Cycle 8 Day 1; no evidence of progressive disease; and undetectable serum or urine M-protein prior to Cycle 6 that remained undetectable. With the exceptions of radiation therapy, surgery or supportive care, as determined by treating physician, no other chemotherapy, experimental medications, other anticancer therapy, immunotherapy, hormonal cancer therapy, radiation, surgery for cancer or experimental medications were permitted while patients were on study treatment.
Efficacy and safety assessments
Efficacy was measured prior to each new cycle of therapy. Each patient's multiple myeloma was assessed at baseline with serum and urine protein electrophoresis (SPEP or UPEP), serum and urine immunofixation electrophoresis (SIFE or UIFE) and SFLC. Each patient's multiple myeloma was assessed during study treatment with SPEP, SIFE, SFLC, and UPEP/UIFE at a study-designated central laboratory prior to every cycle until objective progression was observed in accordance with the International Myeloma Working Group Uniform Response Criteria (Rajkumar et al, 2011) . Best overall response rates were reported by treatment and tested as an ordinal outcome using logistic regression. QoR results were from the logistic regression model, while considering the best overall response as an ordinal, rather than dichotomous, outcome (i.e., sCR > CR > VGPR > PR > MR > SD > PD). If fewer than 5% of patients across treatment arms had a best overall response in a given category, that category was combined with the next lower category for analysis. Thus, the QoR analysis allowed for testing whether there was an overall shift across the distribution to higher levels of response. Duration of response was also evaluated. Pain response was based on the modified Brief Pain Inventory (BPI)-short form (baseline, on-therapy and follow-up).
Patients had a skeletal survey and a bone marrow biopsy prior to randomization. Patients were monitored for Tabalumab, Bortezomib, and Dexamethasone in MM ª 2016 John Wiley & Sons Ltd development of SREs related to multiple myeloma (new pathological fracture, spinal cord compression, surgery to the bone, radiation to the bone) at each cycle. Reduction in the risk of SRE and the lengthening of time to SRE were evaluated as efficacy endpoints. Patients who discontinued study treatment for reasons other than disease progression (but remained on study in follow-up) were followed at the same cycle intervals by the same method(s) used at baseline and during the study treatment period. All patients receiving study therapy were assessed for toxicity before each cycle, with events classified and graded for severity using NCI-CTCAE v. 4.0.
Statistical analyses
All patients enrolled were considered part of the sample and analysed according to the intent-to-treat (ITT) principle. The safety population included all subjects who received 1 or more treatments. Subjects in this population were analysed according to the treatment to which they were randomized. The final analysis was performed after 152 PFS events occurred (i.e., a 34Á3% censoring rate). Patients were randomized using the following stratification factors: International Staging System (ISS; high risk versus standard risk), number of prior lines of therapy (1 vs. >1), response to prior bortezomib (bortezomib na€ ıve or ≥PR lasting ≥6 months versus prior MR or ≥PR lasting <6 months), and measurable disease by SPEP/UPEP versus SFLC only. Patients were considered high risk if they were Stage II or III according to the ISS (Greipp et al, 2005) and were positive for t(4;14), t (14;16) or 17p-on fluorescence in situ hybridization assessment of a bone marrow aspirate.
The study was originally designed as a Phase 2/3 study; the primary objective of the Phase 2 portion was to use the quality of response results to select a dose of tabalumab to evaluate in combination with bortezomib and dexamethasone in Phase 3. However, there was limited power to test the dose effect. The superiority of tabalumab over placebo was evaluated based on the 1-sided P-value for the stratified logrank statistic, adjusted to control type 1 error across interim and final analyses at the 0Á10 level. At the planned primary efficacy analysis, after approximately 140 events, the null hypothesis of no treatment effect of tabalumab for PFS would be rejected if the 1-sided P-value was <0Á0946.
The Cox proportional hazard model (Cox, 1972 ) with treatment as a factor was used to estimate the hazard ratio (HR) and corresponding 95% confidence interval (CI) and Wald's test P-value after adjusting for the potential prognostic variables that were also used for stratification. 
BAFF analyses
B-cell activating factor protein levels were measured from serum samples (taken at baseline and prior to each cycle) using an analytically validated enzyme-linked immunosorbent assay (ELISA) at Pacific Biomarkers, Inc. (Seattle, Washington). The BAFF ELISA is drug-tolerant (i.e., the assay measures BAFF whether or not it is bound by tabalumab). Increases in BAFF levels following administration of tabalumab are expected because the BAFF/tabalumab complex now has the half-life of an antibody and is cleared through normal mechanisms of antibody clearance.
The potential relationships between baseline BAFF expression and PFS and between baseline BAFF expression and objective response rate (ORR) were analysed. In particular, patients were divided into high and low BAFF expression subgroups using the 75th percentile cut-off point and treatment arm (combined tabalumab 100 and 300 mg vs. placebo). The expression class was then analysed against efficacy endpoints (Cox regression: PFS; logistic regression: ORR) using a treatment-dependent interaction model that included dichotomous expression class, treatment indicator, interaction between expression class and treatment, and stratification factors. Interaction P-value, assessing the interaction term, and contrast P-values, assessing treatment effect within each expression class, were based on a likelihood ratio test. Furthermore, a main effects regression model (which excluded the interaction term from the interaction model) was also explored to assess the marker's ability to identify differences in efficacy outcomes, independent of treatment. A 2-sided test with a of 0Á05 was used.
Additional exploratory assessments of potential relationships between BAFF expression and PFS and between BAFF expression and ORR across the continuum of BAFF levels were performed. In particular, contrast treatment HR or odds ratio (OR) in each expression class and corresponding 95% CI were presented in a plot against the continuum of quantile value cut-off points (from 10th to 90th percentiles) of BAFF expression. No multiplicity adjustments across cutoff points or endpoints were made.
PK analyses
Pharmacokinetics analyses were conducted on all patients who received ≥1 dose of tabalumab and had blood samples collected. Tabalumab blood samples were collected on Days 4, 8 and 11 of Cycles 1 and 2, on Day 1 of every subsequent cycle, and at treatment and study discontinuation. Bortezomib blood samples were collected on Days 1, 4, 8 and 11 of Cycle 1. Bortezomib plasma levels were analysed using descriptive methods. Tabalumab serum concentration data were analysed by means of standard noncompartmental methods.
Results
Patient characteristics and disposition
A total of 299 patients entered the study, 220 of whom were randomly assigned to tabalumab 100 mg (N = 74 randomized; N = 73 treated), tabalumab 300 mg (N = 74), or placebo (N = 72) (Fig 1) . The median age of all treated patients was 66Á0 years (range, 38-86 years), 51Á4% were women and 73Á6% were white (Table I) . Fifty-two per cent of the patients had a PS of 0, 46% a PS of 1, and 2% a PS of 2. Immunoglobulin isotypes, cytogenetic chromosomal abnormalities and normal versus high b 2 -microglobulin concentrations were generally well balanced between treatment groups. On average, patients received 2 prior therapies, with 48% of the patients having previously received bortezomib.
Ninety-two of the 219 patients on therapy completed treatment, with progressive disease being the primary reason for treatment discontinuation (Table II) . Discontinuation rates were 63% (46/73) in the tabalumab 100 mg arm, 61% (45/74) in the tabalumab 300 mg arm and 51% (37/72) in the placebo arm.
Efficacy
Median PFS was 6Á6 months for the tabalumab 100 mg group, 7Á5 months for the tabalumab 300 mg group, and 7Á6 months for the placebo group (Table III) . PFS HRs (95% CI) between each tabalumab dose group and placebo did not differ from 1 (100 mg tabalumab vs. placebo 1Á13 [0Á80-1Á59], P = 0Á480; 300 mg tabalumab vs. placebo 1Á03 [0Á72-1Á45], P = 0Á884) and estimated 6-month PFS rates were not significantly different. For OS, 47 events were observed, the medians were not reached, the HRs (95% CI) between each tabalumab dose group and placebo did not differ from 1 (100 mg tabalumab vs. placebo 1Á09 [0Á60-1Á98], P = 0Á789; 300 mg tabalumab vs. placebo 0Á90 [0Á48-1Á67], P = 0Á730) and estimated 1-year survival rates were not significantly different. The overall response rate was 58Á1% for the tabalumab 100 mg group, 59Á5% for the tabalumab 300 mg group, and 61Á1% for the placebo group, with an sCR or CR observed for 4 patients in the tabalumab 100 mg group, 11 in the tabalumab 300 mg group, and 6 in the placebo group. Rates of best overall response are summarized by category in Table III . The marginal odds of patients achieving a higher category of response (QoR) were not significantly higher in the tabalumab 100 mg (OR = 1Á98, P = 0Á401) or 300 mg (OR = 1Á84, P = 0Á455) groups compared to the placebo group. Median time to next treatment did not differ between the placebo group (11Á7 months) and the tabalumab 100 mg (10Á1 months) or 300 mg (9Á9 months) groups. Median time to first SRE was not reached for any treatment group. Thirty-four patients had an evolving response after 8 cycles of treatment and received up to 2 additional cycles: 1 Tabalumab, Bortezomib, and Dexamethasone in MM ª 2016 John Wiley & Sons Ltd patient (1Á4%) in the tabalumab 300 mg arm received 9 cycles and 8 patients (10Á8%) in the tabalumab 300 mg group, 12 (16Á4%) in the tabalumab 100 mg group, and 13 (18Á1%) in the placebo group received 10 cycles.
Treatment arm was not a significant factor in the longitudinal analysis of the change from baseline in the BPI worst pain score. The BPI was administered on each day of bortezomib treatment (Days 1, 4, 8, 11 of each cycle). Only baseline value and day within cycle significantly affected the change in score. The estimated mean was within 1 point of baseline at each assessment day of each cycle. Neither 
Safety
Treatment-emergent adverse events (TEAEs) of any grade were reported by 212 patients (96Á8%), with thrombocytopenia, fatigue, diarrhoea and constipation being the most commonly reported TEAEs overall (Table IV) . The most Two patients died during the study due to AEs that were possibly related to study treatment, 1 in the tabalumab 300 mg group (sepsis) and 1 in the placebo group (intestinal ischaemia).
Correlative analyses of baseline BAFF expression and efficacy outcomes
The distribution of baseline BAFF expression was similar across the 3 treatment arms ( Figure S1 ). Because no N, total population size; n, number of patients. *All were adverse event-related, except one in the tabalumab 300 mg group where no reason was given. N, total population size; NA, not applicable; n, number of patients; PFS, progression-free survival; OS, overall survival. *Quality of response reflects the distribution of best overall responses across all of the categories. The results are from logistic regression model while considering the response as an ordinal outcome, that is, sCR > CR > VGPR > PR > MR > SD > PD. If fewer than 5% of patients across treatment arms had a best overall response in a given category, that category was combined with the next lower category for analysis. †Defined as any one of the following related to multiple myeloma: new pathological fracture, spinal cord compression, surgery to the bone, radiation to the bone.
Tabalumab, Bortezomib, and Dexamethasone in MM ª 2016 John Wiley & Sons Ltd significant differences in efficacy outcomes were observed between the 2 tabalumab dosage groups, the tabalumab groups were combined for the remainder of these analyses. Using the 75th percentile BAFF expression cut-off point (1176 pg/ml), no significant marker-by-treatment interaction effects were observed (interaction P = 0Á352 for PFS and P = 0Á058 for ORR) (data not shown). The median PFS (mPFS) HR comparing tabalumab vs. placebo in patients with high BAFF expression was 0Á8 (95% CI: 0Á41-1Á59, P = 0Á536) ( Figure S2 ). Across treatments, patients with low BAFF expression (n = 162) had significantly longer mPFS compared to those with high BAFF expression (n = 55) using the 75th percentile cut-off point ( Figure S3 ) to assess the relationships between PFS and ORR and BAFF expression along the biomarker continuum (10th to 90th percentile cut-off points). In each of the high and low expression subgroups across the continuum of BAFF expression, no significant treatment differences in PFS or ORR were observed for the 25th to 75th percentile cut-off points (e.g., 95% CIs of HRs and ORs comparing tabalumab and placebo included 1).
Pharmacokinetics
Serum concentration data were available for 139 patients administered 100 or 300 mg tabalumab. Observations below the limit of quantitation of the assay were excluded from analysis. After a single IV administration of 100 or 300 mg tabalumab, both maximum observed plasma concentration (C max ) and area under the plasma concentration-time curve over a dosing interval (AUC 0-s ) increased in a seemingly dose-proportional manner (Table V) . After repeated IV administration, the time course of tabalumab serum concentration was characterized by a mean terminal elimination half-life (t 1/2 ) of 594 h (24Á8 days) and 767 h (32Á0 days) for 100 mg and 300 mg, respectively. At steady state, C max and AUC 0-s increased in a seemingly dose-proportional manner, and the accumulation ratios for C max and AUC 0-s were similar for 100 and 300 mg, further suggesting dose-proportional PK over the dose range investigated. 
Data reported as n (%). N, number of treated patients; n, number of patients with at least one event. *National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade (version 4.0).
A total of 171 patients had bortezomib plasma concentration data available. The peak and trough plasma levels of bortezomib during Cycle 1 were similar across all 3 treatment arms, suggesting no effect of tabalumab on the serum levels of bortezomib (data not shown).
Discussion
The Phase 2 study described in this report was undertaken to compare 100 mg and 300 mg doses of tabalumab combined with dexamethasone and bortezomib to dexamethasone and bortezomib in patients with relapsed or refractory multiple myeloma. This study was initiated following our previous Phase 1 study of tabalumab plus bortezomib in relapsed or refractory multiple myeloma, which showed favourable efficacy and safety results and provided preliminary evidence of a potential relationship between response and baseline BAFF levels (Raje et al, 2016) . We hypothesized that a 300 mg dose of tabalumab might be necessary to provide an adequate level of target neutralization in patients with higher BAFF levels, thereby maximizing the probability of achieving the best possible treatment effect in this patient population. The doses tested in this study yielded tabalumab serum levels similar to those observed in the Phase 1 study. Although tabalumab was generally well tolerated, the primary endpoint of PFS was not improved during treatment with tabalumab compared to placebo and no statistically significant betweengroup differences were found in the secondary efficacy measures. Discontinuation rates were similar between the tabalumab dose arms (63% for 100 mg and 61% for 300 mg), although they were slightly higher than in the placebo arm (51%). Of interest, we did not see a difference in time to first SRE between tabalumab and placebo arms, despite preclinical evidence of decreased osteolytic activity after tabalumab treatment (Neri et al, 2007) ; however, very few SRE events were observed in this study. A higher dose of 300 mg yielded higher tabalumab serum levels, but did not enhance efficacy compared to the 100 mg dose. Despite the disappointing efficacy outcome related to targeting BAFF in conjunction with standard treatment, the results of this trial support the prognostic value of BAFF in patients with multiple myeloma.
The results of this study suggest that, regardless of the strong preclinical rationale, targeting BAFF alone is not sufficient to improve the efficacy of bortezomib and dexamethasone for the treatment of relapsed multiple myeloma, though the reason for this finding is unclear. Unfortunately, our findings are limited by lack of data on the contribution of a proliferation-inducing ligand (APRIL, also termed TNFSF13), another member of the TNF alpha superfamily of cytokines involved in the pathophysiology of multiple myeloma (Bossen & Schneider, 2006) , as a survival factor for multiple myeloma in the patients who had BAFF neutralized. APRIL has higher affinity than BAFF to B-cell maturation antigen (BCMA, TNFRSF17), which activates survival signals (39) 47Á9 (51) 69Á0 (51) 103 (43) 131 (40) 189 ( allowing multiple myeloma cells to escape apoptosis (Novak et al, 2004; Bossen & Schneider, 2006; Carpenter et al, 2013) . These findings have led to the development of novel mAbs that target both BAFF and APRIL (e.g., atacicept), as well as those that target BCMA, for the treatment of multiple myeloma (Rossi, 2011; Carpenter et al, 2013; Tai & Anderson, 2015) . Another limitation is that we did not investigate the potential role of other cytokines, such as IL6, which promotes multiple myeloma cell growth and is thought to be involved in the development of drug resistance (Lauta, 2003; Alexandrakis et al, 2013) . Another potential explanation for lack of efficacy of tabalumab involves the BAFF receptor Transmembrane Activator and CAML Interactor (TACI, TNFRSF13B). Recent reports describe decreased TNFRSF13B (also termed TACI) gene expression by multiple myeloma cells (Moreaux et al, 2004 (Moreaux et al, , 2005 , which might suggest a decreased dependence on the microenvironment and possibly less benefit from inhibition of the BAFF pathway in multiple myeloma. In addition, lower TNFRSF13B gene expression was found in relapsed multiple myeloma compared to newly diagnosed multiple myeloma (Neri et al, 2007) . Based on this preclinical information, the possibility exists that tabalumab might show more evidence of activity when administered in a front-line setting in patients with multiple myeloma. The clinical efficacy of immunomodulatory drugs (IMiDs), such as lenalidomide, has been attributed to multiple effects including inhibition of pro-survival and pro-growth factors (i.e., IL6), which, in turn, decreases multiple myeloma stromal support (Chanan-Khan, 2011) . Both thalidomide and pomalidomide have been shown to reduce secretion of IL6 by 87% in co-cultures of multiple myeloma (HS Sultan cells) and stromal cells (Gupta et al, 2001; Chanan-Khan, 2011) . Lenalidomide and pomalidomide have also been shown to decrease expression of adhesion molecules that are needed for the formation of osteoclasts (Bolzoni et al, 2013) . Therefore, it might be of interest to investigate the potential synergy of tabalumab in combination with an IMiD.
The results of our correlative analyses of baseline BAFF expression and efficacy support the prognostic value of BAFF in patients with multiple myeloma. We found that patients with low baseline BAFF expression (75th percentile cut-off point) had significantly longer PFS compared to patients with high baseline BAFF expression, independent of treatment. Our results are consistent with those from the previous Phase 1 tabalumab study in previously-treated multiple myeloma patients, which reported that none of the 9 patients who had baseline BAFF levels >1500 pg/ml had a best overall response of PR or better, whereas 19 of the 37 patients with baseline BAFF <1500 pg/ml had a response (Raje et al, 2016) . Our results are also consistent with reports of significantly shorter survival among newly diagnosed, treatmentna€ ıve multiple myeloma patients who had BAFF values that were higher than the median of all multiple myeloma patients (Fragioudaki et al, 2012; Lemancewicz et al, 2013) . Finally, we examined whether there might be a correlation between baseline BAFF expression and tabalumab treatment activity by examining different cut-off points of baseline BAFF levels, and found no statistically significant difference. However, given the relatively small sample sizes in this exploratory analysis, more extensive investigation in larger patient populations is needed before any solid conclusions can be drawn.
The TEAEs observed during treatment with tabalumab in combination with bortezomib and dexamethasone were consistent with those observed with bortezomib, such as fatigue, gastrointestinal disturbances and haematological disturbances (Merin & Kelly, 2014) . Peripheral neuropathy, which is the primary dose-limiting toxicity reported during treatment with bortezomib (Argyriou et al, 2008) , was also observed with similar frequencies in the tabalumab and placebo groups. It is important to note the low incidence of neutropenia observed in this trial (6Á8% and 11Á0% for 300 and 100 mg tabalumab arms, respectively), which further supports the generally favourable safety profile of tabalumab.
In conclusion, this Phase 2 study found that the efficacy of tabalumab combined with bortezomib and dexamethasone was not significantly different to that of bortezomib and dexamethasone in relapsed or refractory multiple myeloma and that increasing the dosage of tabalumab from 100 to 300 mg did not improve efficacy. Despite the disappointing efficacy outcome, a better understanding of BAFF in multiple myeloma treatment as a result of this study is an important contribution to the literature. NG has received honoraria from Mundipharma and Celgene; SAH has participated on advisory panels for Celgene and Amgen; AP has received honoraria, consultancy fees, and/or research funding from Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, and Sanofi Aventis and has participated on a speaker's bureau for Bristol-Myers Squibb. AO, S-YH, and KK report no conflicts of interest. 
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Additional Supporting Information may be found in the online version of this article: Fig S1 . Distribution of baseline BAFF expression by ELISA by treatment group. LY100, tabalumab 100 mg; LY300, tabalumab 300 mg; Min, minimum; Max, maximum; N, number of subjects within the category; Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation. Fig S2. Kaplan Meier plot of PFS for dichotomized BAFF expression by ELISA (high/low) and by treatment arm (A) and in combined treatment arm (B). BAFF expression by ELISA is dichotomized into high and low expression subgroups using the 75th percentile cut-off point. LY, tabalumab; n, number of patients within specified subgroup; n.event, number of events within specified subgroup; trt, treatment. Fig S3. Hazard ratio (HR) diagnostic plot of progressionfree survival (PFS) (A) and odds ratio (OR) diagnostic plot of objective response rate (ORR) (B) for dichotomized BAFF expression by ELISA along the BAFF expression continuum (10th-90th percentile assessment). In particular, at each of the quantile values between 10th and 90th percentile, inclusive, of BAFF expression, patients were divided into subgroups defined by high (≥quantile value) or low (<quantile value) expression and treatment arm (combined tabalumab 100 and 300 mg vs. placebo). An interaction model was performed for each of the quantile cut-off point: Cox regression of PFS (A) or logistic regression of response rate (B) as function of treatment, dichotomous marker, interaction term between treatment and dichotomous marker adjusting for stratification factors of ISS risk category, number of lines of prior therapy, baseline disease assessment method, and response to prior bortezomib therapy. HR (A) or OR (B) and corresponding 95% CIs are obtained for the contrast treatment comparison within the expression class, and are plotted along the biomarker continuum. Lower x-axis: quantiles of the marker distribution; upper x-axis: actual values corresponding to the quantiles of the marker distribution. LY, tabalumab; trt, treatment.
